Evidence map›Paper›PMID 40413692›Full record

ArticleClinical and experimental medicine2025

Is high IgG level associated with disease activity and organ damage in patients with Sjögren's syndrome? A 3-year follow-up cohort study.

Yueting Li, Siyun Chen, Li Guo, Chuhan Wang, Yanhong Wang, Jiuliang Zhao, Dong Xu, Mengtao Li, Xiaofeng Zeng, Yan Zhao

Abstract read
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yueting Li *Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.
Siyun Chen *Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.
Li Guo *Department of Rheumatology and Immunology, The Second People's Hospital of Fuyang City, Anhui Province, Fuyang, 236000, China.
Chuhan WangDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.
Yanhong WangDepartment of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, School of Basic Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, People's Republic of China.
Jiuliang ZhaoDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.
Dong XuDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China. xudong74@hotmail.com.
Mengtao LiDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.
Xiaofeng ZengDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.
Yan ZhaoDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.

Funding

CAMS Innovation Fund for Medical Sciences (CIFMS) 2021-I2M-1-005Chinese National Key Technology R&D Program, Ministry of Science and Technology 2017YFC0907601, 2017YFC0907605National High-Level Hospital Clinical Research Funding 2022-PUMCH-B-013
6 · The paper itself

Abstract

Hypergammaglobulinemia is prevalent in primary Sjögren's syndrome (pSS) and is considered a marker of disease activity. However, limited data exist regarding its association with disease activity and organ damage. We enrolled patients with pSS from the Chinese Rheumatism Data Centre and categorized them into four groups based on the IgG levels over a 3-year follow-up: consistently high, consistently intermediate, consistently normal, and intermittent. Disease activity and organ damage at the end of the third year were compared across these groups. A total of 351 patients were included in this study, all females with a median age of 45 (IQR 35-53) years. The median baseline IgG was 17.2 (IQR 13.4-21.4) g/L. About 40% of the patients with elevated baseline IgG levels remained in the consistently high or intermediate IgG group. Compared to patients with consistently normal IgG levels, those with consistently high IgG levels had higher median SSDDI scores (2 vs. 1, p = 0.014), higher median ESSPRI scores (2.5 vs. 1.7, p = 0.005), more extra-glandular organ manifestations (IRR 2.34, 95%CI 1.48-3.7, p = < 0.001), and more extra-glandular organ damage (IRR 2.06, 95%CI 1.03-4.12, p = 0.040) at the third-year follow-up. No significant differences in extra-glandular involvement were found between the consistently intermediate IgG group and the consistently normal IgG group. The consistently high IgG level, but not the consistently intermediate level, was associated with a greater number of extra-glandular manifestations and increased extra-glandular organ damage.

Indexed as

HypergammaglobulinemiaImmunoglobulin GSjogren's SyndromeAdultBiomarkersFemaleFollow-Up StudiesHumansMiddle AgedSeverity of Illness IndexBiomarkersImmunoglobulin GDisease activityHypergammaglobulinemiaOrgan damagePrimary Sjögren’s syndrome

Identifiers

PMID40413692
PMCPMC12104097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.